Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Pancreatic Neoplasms

Cholangiocarcinoma

Adenocarcinoma

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Pancreatic Cancer

Bile Duct Cancer

"Conventional" method of pathological evaluation

LEEPP includes: 1) multicolor inking; 2) axial slicing; 3) circumferential margin; 4) 1-mm clearance

Leeds Pathology Protocol (LEEPP)

This multicentric prospective randomized controlled trial (RCT) compares the Leeds Pathology Protocol (LEEPP) with other "conventional" pathological protocol of PD specimen for periampullary cancer. Our aims were to evaluate the impact of the protocol and of the clearance on R1 rate and its prognostic value.

Margin Status After Pancreaticoduodenectomy for Cancer

Margin Status After Pancreaticoduodenectomy for Cancer. Results of a Multicentric Prospective Randomized Trial

To evaluate difference in terms of R1 resection rates between study groups with 0-mm and 1-mm clearance

To evaluate differences in pathological results (T status, N status, number of blocks, number of lymphnodes, etc) between the two study groups

To evaluate the correlation between R1 resection and oncological results (local recurrence, overall survival) in the two study groups

Humanitas Hospital, Italy

Azienda Ospedaliero, Universitaria Pisana

Medical University of Silesia

Campus Bio-Medico University

M.D.

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Antimetabolites

gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles.

gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.

gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles

TS-1 with radiation

Bai Chunmei, MD

Cheng Yuejuan, MD

Yuejuan Cheng, M.D.

Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes after curative resection.

Adjuvant Gemcitabine Versus Gemcitabine With TS-1 based Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes after curative resection: a randomized phase II study.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Margin Status After Pancreaticoduodenectomy for Cancer	NCT03267966	Pancreatic Canc... Cholangiocarcin... Ampullary Cance...	Leeds Pathology...	18 Years -	Campus Bio-Medico University
Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes	NCT02754180	Pancreatic Neop...	Gemcitabine TS-1 with radia...	18 Years - 75 Years	Peking Union Medical College Hospital
Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes	NCT02754180	Pancreatic Neop...	Gemcitabine TS-1 with radia...	18 Years - 75 Years	Peking Union Medical College Hospital
Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes	NCT02754180	Pancreatic Neop...	Gemcitabine TS-1 with radia...	18 Years - 75 Years	Peking Union Medical College Hospital

Spots Global Cancer Trial Database for r1 resection

Every month we try and update this database with for r1 resection cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.